Loading...
VETO
XPAR
Market cap1.12bUSD
Nov 20, Last price  
85.70EUR
1D
-0.70%
1Q
21.56%
Jan 2017
88.23%
IPO
272.61%
Name

Vétoquinol

Chart & performance

D1W1MN
XPAR:VETO chart
P/E
17.77
P/S
1.94
EPS
4.82
Vol. 1Y
30.69%
Shs. 5Y
0.09%
Rev. 5Y
4.22%
Div Yld LY
1.04%
Div Yld TTM
1.09%
Revenues
526m
-2.50%
211,591,000233,364,000234,395,000257,057,000282,041,000284,137,000298,293,000299,727,000315,298,000342,612,000350,354,000352,173,000367,941,000395,990,000427,467,000521,272,000539,779,000529,271,000539,196,000525,700,000
Net income
57m
-2.36%
15,824,00018,642,00018,564,00018,207,00022,255,00022,695,00022,569,00023,580,00025,766,00024,156,00027,827,00034,831,00036,259,00028,589,00019,221,00062,861,00047,995,00055,560,00058,685,00057,300,000
CFO
72m
-16.02%
23,356,00037,215,00021,903,00040,046,00034,360,00029,992,00034,209,00028,106,00041,298,00038,897,00043,205,00041,225,00037,884,00052,024,00092,012,00089,715,00062,855,00089,391,00085,826,00072,076,000
Dividend
Jun 03, 20260.93 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Vetoquinol S.A. is a prominent veterinary pharmaceutical enterprise dedicated to the innovation, development, and global commercialization of both medicinal and non-medicinal solutions for animal health. Its operations extend across Europe, the Americas, and the Asia Pacific regions. The company's diverse product portfolio addresses crucial therapeutic areas, including mobility, pain management, and inflammation; dermatological care and hygiene; anti-parasitic treatments; udder health; infectious disease control; reproductive solutions; behavior modification; internal medicine; and cardiovascular-renal support. These offerings cater to a wide spectrum of animals, encompassing livestock such as cattle, sheep, pigs, and poultry, alongside companion animals like dogs. Founded in 1933, Vetoquinol S.A. is headquartered in Lure, France, and functions as a subsidiary of Soparfin SCA.

Related entities

Parent
SOPARFIN
Subsidiaries
VETOQUINOL INTERNATIONAL

Key people

Matthieu Frechin
Chairman of the Board, Chief Executive Officer · since 2023
Alain Masson
Deputy Chief Executive Officer and Head Pharmacist, Group Quality Director · since 2020
Dominique Derveaux
Group Chief Operating Officer · since 2020
Nathalie Arlecchini
Group Human Resources Director · since 2025
Audrey Chanoinat
Director · since 2021
M. Luc Frechin
Director · since 2021
Philippe Arnold
Independent Director · since 2020
Marie-Josephe Baud
Independent Director · since 2020
Louis Champel
Independent Director · since 2020
Anne Graffin
Independent Director · since 2022
IPO date
Nov 16, 2006
Employees
2,455
Domiciled in
FR
Incorporated in
FR
Headquarters & legal address
Village
MAGNY-VERNOIS 70200
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT